|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Multicenter study of endoscopic preoperative biliary drainage for malignant distal biliary obstruction显示文摘AIM: To determine the optimal method of endoscopic preoperative biliary drainage for malignant distal biliary obstruction.METHODS: Multicenter retrospective study was conducted in patients who underwent plastic stent(PS) or nasobiliary catheter(NBC) placement for resectable malignant distal biliary obstruction followed by surgery between January 2010 and March 2012. Procedurerelated adverse events, stent/catheter dysfunction(occlusion or migration of PS/NBC, developmentof cholangitis, or other conditions that required repeat endoscopic biliary intervention), and jaundice resolution(bilirubin level < 3.0 mg/d L) were evaluated. Cumulative incidence of jaundice resolution and dysfunction of PS/NBC were estimated using competing risk analysis. Patient characteristics and preoperative biliary drainage were also evaluated for association with the time to jaundice resolution and PS/NBC dysfunction using competing risk regression analysis.RESULTS: In total, 419 patients were included in the study(PS, 253 and NBC, 166). Primary cancers included pancreatic cancer in 194 patients(46%), bile duct cancer in 172(41%), gallbladder cancer in three(1%), and ampullary cancer in 50(12%). The median serum total bilirubin was 7.8 mg/d L and 324 patients(77%) had ≥ 3.0 mg/d L. During the median time to surgery of 29 d [interquartile range(IQR), 30-39 d]. PS/NBC dysfunction rate was 35% for PS and 18% for NBC [Subdistribution hazard ratio(SHR) = 4.76; 95%CI: 2.44-10.0, P < 0.001]; the pig-tailed tip was a risk factor for PS dysfunction. Jaundice resolution was achieved in 85% of patients and did not depend on the drainage method(PS or NBC).CONCLUSION: PS has insufficient patency for preoperative biliary drainage. Given the drawbacks of external drainage via NBC, an alternative method of internal drainage should be explored. | Naoki Sasahira Tsuyoshi Hamada Osamu Togawa Ryuichi Yamamoto Tomohisa Iwai Kiichi Tamada Yoshiaki Kawaguchi Kenji Shimura Takero Koike Yu Yoshida Kazuya Sugimori Shomei Ryozawa Toshiharu Kakimoto Ko Nishikawa Katsuya Kitamura Tsunao Imamura Masafumi Mizuide Nobuo Toda Iruru Maetani Yuji Sakai Takao Itoi Masatsugu Nagahama Yousuke Nakai Hiroyuki Isayama | 2016 | World Journal of Gastroenterology2016，22，14： | 18 |
| 2 | Improvement of prognosis for unresectable biliary tract cancer显示文摘AIM:To evaluate the chemotherapeutic outcomes and confirm the recent improvement of prognosis for unresectable biliary tract cancer.METHODS:A total of 186 consecutive patients with unresectable biliary tract cancer,who had been treated with chemotherapy between 2000 and 2009 at five institutions in Japan,were retrospectively analyzed.These patients were divided into three groups based on the year beginning chemotherapy:Group A(2000-2003),Group B(2004-2006),and Group C(2007-2009).The data were fixed at the end of December 2011.Overall survival and time-to-progression were analyzed and compared chronologically.RESULTS:No patient characteristics were significantly different among the three groups.The gallbladder was involved in about half of the patients in each group,and metastatic biliary tract cancer was present in three quarters of the enrollees.In Group A,5-fluorouracilbased chemotherapies were primarily selected as firstline chemotherapy,and only 24% were treated with second-line chemotherapy.In Group B,gemcitabine or S-1 monotherapy was mainly introduced as firstline chemotherapy,and 51% of the patients who were refractory to first-line chemotherapy were treated with second-line chemotherapy mainly with monotherapy.In Group C,the combination therapy with gemcitabine and S-1 was mainly chosen as first-line chemotherapy,and 53% of the patients refractory to first-line chemotherapy were treated with second-line chemotherapy mainly with combination therapy.The median timeto-progressions were 4.4 mo,3.5 mo and 5.9 mo in Groups A,B and C,respectively(4.4 mo vs 3.5 mo vs 5.9 mo,P < 0.01).The median overall survivals were 7.1,7.3,and 11.7 mo in Groups A,B and C(7.1 mo vs 7.3 mo vs 11.7 mo,P = 0.03).Induction rates of all three drugs(gemcitabine,platinum analogs,and fluoropyrimidine) in Groups A,B and C were 4%,2% and 27%(4% vs 2% vs 27%,P < 0.01).CONCLUSION:The prognosis of unresectable biliary tract cancer has improved recently.Using three effective drugs(gemcitabine,platinum analogs,and fluoropyrimidine) may improve the prognosis of this cancer. | Takashi Sasaki Hiroyuki Isayama Yousuke Nakai Naminatsu Takahara Naoki Sasahira Hirofumi Kogure Suguru Mizuno Hiroshi Yagioka Yukiko Ito Natsuyo Yamamoto Kenji Hirano Nobuo Toda Minoru Tada Masao Omata Kazuhiko Koike | 2013 | World Journal of Gastroenterology2013，19，1： | 8 |
| 3 | Clinical analysis of high serum IgE in autoimmune pancreatitis显示文摘AIM: To clarify the clinical significance of high serum IgE in autoimmune pancreatitis (AIP). METHODS: Forty-two AIP patients, whose IgE was measured before steroid treatment, were analyzed. To evaluate the relationship between IgE levels and the disease activity of AIP, we examined (1) Frequency of high IgE (> 170 IU/mL) and concomitant allergic dis-eases requiring treatment; (2) Correlations between IgG, IgG4, and IgE; (3) Relationship between the presence of extrapancreatic lesions and IgE; (4) Re-lationship between clinical relapse and IgE in patients treated with steroids, and (5) Transition of IgE before and after steroid treatment. RESULTS: IgE was elevated in 36/42 (86%) patients.Concomitant allergic disease was observed in seven patients (allergic rhinitis in three, bronchial asthma in three, and urticaria in one). There were no signifi-cant correlations between IgG, IgG4, and IgE (r = -0.168 for IgG, and r = -0.188 for IgG4). There was no significant difference in IgE in the patients with and without extrapancreatic lesions (526 ± 531 IU/mL vs 819 ± 768 IU/mL, P = 0.163), with and without clini-cal relapse (457 ± 346 IU/mL vs 784 ± 786 IU/mL, P = 0.374). There was no significant difference in IgE between before and after steroid treatment (723 ± 744 IU/mL vs 673 ± 660 IU/mL, P = 0.633). CONCLUSION: Although IgE does not necessarily reflect the disease activity, IgE might be useful for the diagnosis of AIP in an inactive stage. | Kenji Hirano Minoru Tada Hiroyuki Isayama Kazumichi Kawakubo Hiroshi Yagioka Takashi Sasaki Hirofumi Kogure Yousuke Nakai Naoki Sasahira Takeshi Tsujino Nobuo Toda Kazuhiko Koike | 2010 | World Journal of Gastroenterology2010，16，41： | 4 |
| 4 | Efficacy of tolvaptan in patients with refractory ascites in a clinical setting显示文摘AIM: To elucidate the efficacies of tolvaptan(TLV) as a treatment for refractory ascites compared with conventional treatment. METHODS: We retrospectively enrolled 120 refractory ascites patients between January 1, 2009 and September 31, 2014. Sixty patients were treated with oral TLV at a starting dose of 3.75 mg/d in addition to sodium restriction(> 7 g/d), albumin infusion(10-20 g/wk), and standard diuretic therapy(20-60 mg/d furosemide and 25-50 mg/d spironolactone) and 60 patients with large volume paracentesis in addition to sodium restriction(less than 7 g/d), albumin infusion(10-20 g/wk), and standard diuretic therapy(20-120 mg/d furosemide and 25-150 mg/d spironolactone). Patient demographics and laboratory data, including liver function, were not matched due to the small number of patients. Continuous variables were analyzed by unpaired t-test or paired t-test. Fisher's exact test was applied in cases comparing two nominal variables. We analyzed factors affecting clinical outcomes using receiver operating characteristic curves and multivariate regression analysis. We also used multivariate Cox's proportional hazard regression analysis to elucidate the risk factors that contributed to the increased incidence of ascites.RESULTS: TLV was effective in 38(63.3%) patients. The best cut-off values for urine output and reduced urine osmolality as measures of refractory ascites improvement were > 1800 mL within the first 24 h and > 30%, respectively. Multivariate regression analysis indicated that > 25% reduced urine osmolality [odds ratio(OR) = 20.7; P < 0.01] and positive hepatitis C viral antibodies(OR = 5.93; P = 0.05) were positively correlated with an improvement of refractory ascites, while the total bilirubin level per 1.0 mg/dL(OR = 0.57;P = 0.02) was negatively correlated with improvement. In comparing the TLV group and controls, only the serum sodium level was significantly lower in the TLV group(133 mE q/L vs 136 mE q/L; P = 0.02). However, there were no significant differences in the other parameters between the two groups. The cumulative incidence rate was significantly higher in the control group with a median incidence time of 30 d in the TLV group and 20 d in the control group(P = 0.01). Cox hazard proportional multivariate analysis indicated that the use of TLV(OR = 0.58; P < 0.01), uncontrolled liver neoplasms(OR = 1.92; P < 0.01), total bilirubin level per 1.0 mg/dL(OR = 1.10; P < 0.01), and higher sodium level per 1.0 m Eq/L(OR = 0.94; P < 0.01) were independent factors that contributed to incidence. CONCLUSION: Administration of TLV results in better control of refractory ascites and reduced the incidence of additional invasive procedures or hospitalization compared with conventional ascites treatments. | Takamasa Ohki Koki Sato Tomoharu Yamada Mari Yamagami Daisaku Ito Koki Kawanishi Kentaro Kojima Michiharu Seki Nobuo Toda Kazumi Tagawa | 2015 | World Journal of Hepatology2015，7，12： | 4 |
| 5 | Risk factors for pancreatitis following transpapillary self-expandable metal stent placement显示文摘 | Kazumichi Kawakubo Hiroyuki Isayama Yousuke Nakai Osamu Togawa Naoki Sasahira Hirofumi Kogure Takashi Sasaki Saburo Matsubara Natsuyo Yamamoto Kenji Hirano Takeshi Tsujino Nobuo Toda Minoru Tada Masao Omata Kazuhiko Koike | 2012 | Surgical Endoscopy2012，，3： | 2 |
| 6 | Outcomes after clearance of pancreatic stones with or without pancreatic stenting显示文摘 | Naoki Sasahira Minoru Tada Hiroyuki Isayama Kenji Hirano Yousuke Nakai Natsuyo Yamamoto Takeshi Tsujino Nobuo Toda Yutaka Komatsu Haruhiko Yoshida Takao Kawabe Masao Omata | 2007 | Journal of Gastroenterology2007，，1： | 2 |
| 7 | Measurement of radial and axial forces of biliary self-expandable metallic stents显示文摘 | Hiroyuki Isayama Yousuke Nakai Yoshihide Toyokawa Osamu Togawa Chimyon Gon Yukiko Ito Yoko Yashima Hiroshi Yagioka Hirofumi Kogure Takashi Sasaki Toshihiko Arizumi Saburo Matsubara Natsuyo Yamamoto Naoki Sasahira Kenji Hirano Takeshi Tsujino Nobuo Toda Mi | 2009 | Gastrointestinal Endoscopy2009，，1： | 2 |
| 8 | Cholecystitis After Metallic Stent Placement in Patients With Malignant Distal Biliary Obstruction显示文摘 | Hiroyuki Isayama Takao Kawabe Yousuke Nakai Takeshi Tsujino Naoki Sasahira Natsuyo Yamamoto Toshihiko Arizumi Osamu Togawa Saburou Matsubara Yukiko Ito Takashi Sasaki Kenji Hirano Nobuo Toda Yutaka Komatsu Minoru Tada Haruhiko Yoshida Masao Omata | 2006 | Clinical Gastroenterology and Hepatology2006，，9： | 1 |
| 9 | Detection of common bile duct stones: comparison between endoscopic ultrasonography, magnetic resonance cholangiography, and helical-computed-tomographic cholangiography显示文摘 | Shintaro Kondo Hiroyuki Isayama Masaaki Akahane Nobuo Toda Naoki Sasahira Yosuke Nakai Natsuyo Yamamoto Kenji Hirano Yutaka Komatsu Minoru Tada Haruhiko Yoshida Takao Kawabe Kuni Ohtomo Masao Omata | 2004 | European Journal of Radiology2004，，2： | 1 |
| 10 | Mobilization of bone marrow-derived mesenchymal stem cells into the injured tissues after intraarticular injection and their contribution to tissue regeneration显示文摘 | Muhammad Agung Mitsuo Ochi Shinobu Yanada Nobuo Adachi Yasunori Izuta Takuma Yamasaki Katsuhiro Toda | 2006 | Knee Surgery Sports Traumatology Arthroscopy2006，，12： | 1 |
| 11 | Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine显示文摘 | Takashi Sasaki Hiroyuki Isayama Yousuke Nakai Suguru Mizuno Keisuke Yamamoto Hiroshi Yagioka Yoko Yashima Kazumichi Kawakubo Hirofumi Kogure Osamu Togawa Saburo Matsubara Yukiko Ito Naoki Sasahira Kenji Hirano Takeshi Tsujino Nobuo Toda Minoru Tada Masao | 2012 | Investigational New Drugs2012，，2： | 1 |
| 12 | Erectile dysfunction in patients with chronic viral liver disease: its relevance to protein malnutrition显示文摘 | Katsuhisa Toda Yoshiyuki Miwa Shoko Kuriyama Hideki Fukushima Makoto Shiraki Nobuo Murakami Makoto Shimazaki Yoichiro Ito Toshiyuki Nakamura Jun’ichi Sugihara Eiichi Tomita Chisato Nagata Kazutomo Suzuki Hisataka Moriwaki | 2005 | Journal of Gastroenterology2005，，9： | 1 |
| 13 | Efficacy of percutaneous radiofrequency ablation for hepatocellular carcinoma treatment in patients aged≥80 years显示文摘Background:Although radiofrequency ablation(RFA)is a minimally invasive treatment for early-stage hepatocellular carcinoma(HCC),it remains unclear whether RFA achieves favorable outcomes in pa-tients aged≥80 years.This study aimed to determine the efficacy and safety of RFA for HCC in patients aged≥80 years.Methods:A total of 512 naïve patients with HCC who had undergone RFA from January 2001 to December 2016 were enrolled.They were categorized into the≥80-year-old group and the control group(aged<80 years).The primary endpoint was overall survival(OS),and the secondary endpoints were recurrence-free survival,complications associated with RFA,and cause of death.Propensity score matching was performed to adjust for patients’sex,liver function,tumor number,tumor diameter,and hepatitis C virus infection.Finally,the data of 68 patients in the≥80-year-old group and 68 in the control group were analyzed;their baseline characteristics,primary endpoint,and secondary endpoints were compared.Results:There were significant differences in the alanine aminotransferase level and prothrombin time between the groups.The cumulative OS rate was not significantly different between the groups(P=0.83):98.5%,87.9%,and 50.5%in the≥80-year-old group and 94.1%,72.8%,and 49.3%in the control group at 1,3,and 5 years,respectively.Age≥80 years was not significantly associated with OS in multivariate analyses.Liver-related death occurred in 17 patients in the≥80 year-old group and in 16 patients in the control group(P=1.00).Conclusions:RFA is safe and effective for the treatment of patients with HCC aged≥80 years. | Kyohei Tsuchiya Takamasa Ohki Koki Sato Mayuko Kondo Nobuo Toda Kazumi Tagawa | 2020 | Liver Research2020，4，4： | 1 |
| 14 | Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine显示文摘 | Takashi Sasaki Hiroyuki Isayama Yousuke Nakai Suguru Mizuno Keisuke Yamamoto Hiroshi Yagioka Yoko Yashima Kazumichi Kawakubo Hirofumi Kogure Osamu Togawa Saburo Matsubara Yukiko Ito Naoki Sasahira Kenji Hirano Takeshi Tsujino Nobuo Toda Minoru Tada Masao | 2012 | Investigational New Drugs2012，，2： | 1 |
| 15 | Duodenal metal stent placement is a risk factor for biliary metal stent dysfunction: an analysis using a time-dependent covariate显示文摘 | Tsuyoshi Hamada Yousuke Nakai Hiroyuki Isayama Takashi Sasaki Hirofumi Kogure Kazumichi Kawakubo Naoki Sasahira Natsuyo Yamamoto Osamu Togawa Suguru Mizuno Yukiko Ito Kenji Hirano Nobuo Toda Minoru Tada Kazuhiko Koike | 2013 | Surgical Endoscopy2013，，4： | 1 |
| 16 | Serum IgG4 concentrations in pancreatic and biliary diseases显示文摘 | Kenji Hirano Takao Kawabe Natsuyo Yamamoto Yousuke Nakai Naoki Sasahira Takeshi Tsujino Nobuo Toda Hiroyuki Isayama Minoru Tada Masao Omata | 2005 | Clinica Chimica Acta2005，，1： | 1 |
| 17 | Cholecystitis After Metallic Stent Placement in Patients With Malignant Distal Biliary Obstruction显示文摘 | Hiroyuki Isayama Takao Kawabe Yousuke Nakai Takeshi Tsujino Naoki Sasahira Natsuyo Yamamoto Toshihiko Arizumi Osamu Togawa Saburou Matsubara Yukiko Ito Takashi Sasaki Kenji Hirano Nobuo Toda Yutaka Komatsu Minoru Tada Haruhiko Yoshida Masao Omata | 2006 | Clinical Gastroenterology and Hepatology2006，，9： | 1 |
| 18 | Results of the Tokyo Trial of Prevention of Post-ERCP Pancreatitis with Risperidone-2: a multicenter, randomized, placebo-controlled, double-blind clinical trial显示文摘 | Rie Uchino Hiroyuki Isayama Takeshi Tsujino Naoki Sasahira Yukiko Ito Saburo Matsubara Naminatsu Takahara Toshihiko Arizumi Nobuo Toda Dai Mohri Osamu Togawa Hiroshi Yagioka Yoshitsugu Yanagihara Katsuyoshi Nakajima Dai Akiyama Tsuyoshi Hamada Koji Miyaba | 2013 | Gastrointestinal Endoscopy2013，，6： | 1 |
| 19 | A randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine monotherapy for advanced biliary tract cancer显示文摘 | Takashi Sasaki Hiroyuki Isayama Yousuke Nakai Yukiko Ito Ichiro Yasuda Nobuo Toda Hirofumi Kogure Keiji Hanada Hiroyuki Maguchi Naoki Sasahira Hideki Kamada Tsuyoshi Mukai Yoshihiro Okabe Osamu Hasebe Iruru Maetani Kazuhiko Koike | 2013 | Cancer Chemotherapy and Pharmacology2013，，4： | 1 |
| 20 | Pancreatic Cancer in Patients With Pancreatic Cystic Lesions: A Prospective Study in 197 Patients显示文摘 | Minoru Tada Takao Kawabe Masatoshi Arizumi Osamu Togawa Saburo Matsubara Natsuyo Yamamoto Yosuke Nakai Naoki Sasahira Kenji Hirano Takeshi Tsujino Keisuke Tateishi Hiroyuki Isayama Nobuo Toda Haruhiko Yoshida Masao Omata | 2006 | Clinical Gastroenterology and Hepatology2006，，10： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员